Citation Impact
Citing Papers
Epidemiological characteristics of platelet aggregability.
1985
Detection of activated platelets in whole blood using activation- dependent monoclonal antibodies and flow cytometry
1987
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
2008 Standout
Mechanisms of Thrombus Formation
2008 Standout
Clopidogrel with or without Omeprazole in Coronary Artery Disease
2010 Standout
Tumour-derived microvesicles carry several surface determinants and mRNA of tumour cells and transfer some of these determinants to monocytes
2005
Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease
2007
Nucleotide signalling during inflammation
2014 StandoutNature
Transfusion Strategies for Acute Upper Gastrointestinal Bleeding
2013 Standout
Safety, Tolerability, and Initial Efficacy of AZD6140, the First Reversible Oral Adenosine Diphosphate Receptor Antagonist, Compared With Clopidogrel, in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome
2007
Variability in Individual Responsiveness to Clopidogrel
2007
Bivalirudin during Primary PCI in Acute Myocardial Infarction
2008 Standout
Cytochrome P-450 Polymorphisms and Response to Clopidogrel
2008 Standout
Colloid solutions for fluid resuscitation
2003
New Antithrombotic Drugs
2012
Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor gene in mice
1995 StandoutNatureNobel
Shedding microvesicles: artefacts no more
2009
The case for better research standards in peripheral thrombolysis: Poor quality of randomized trials during the past decade
1996
Emergency Hospitalizations for Adverse Drug Events in Older Americans
2011 Standout
Aspirin plus Clopidogrel as Secondary Prevention after Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis
2014 Standout
A perspective on the potential problems with aspirin as an antithrombotic agent: a comparison of studies in an animal model with clinical trials
1999
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
2009 Standout
Complementation of reduced survival, hypotension, and renal abnormalities in angiotensinogen-deficient mice by the human renin and human angiotensinogen genes.
1997 StandoutNobel
Defects in secretion, aggregation, and thrombus formation in platelets from mice lacking Akt2
2004
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
2010
Glycoprotein IIb/IIIa and P2Y12receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses
2005
Genetically programmed chiral organoborane synthesis
2017 StandoutNatureNobel
Platelet Activation and Atherothrombosis
2007 Standout
Incidence of Dyspnea and Assessment of Cardiac and Pulmonary Function in Patients With Stable Coronary Artery Disease Receiving Ticagrelor, Clopidogrel, or Placebo in the ONSET/OFFSET Study
2010
Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: Results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial
2007
The ATP-gated P2X1 Receptor Plays a Pivotal Role in Activation of Aspirin-treated Platelets by Thrombin and Epinephrine
2008 StandoutNobel
Potentiation of platelet activation through the stimulation of P2X1 receptors
2003
Ticagrelor
2011
Type 2 diabetes
2017 Standout
Two functionally distinct α2-adrenergic receptors regulate sympathetic neurotransmission
1999 StandoutNatureNobel
Highly Stereoselective Biocatalytic Synthesis of Key Cyclopropane Intermediate to Ticagrelor
2016 StandoutNobel
The Efficacy and Safety of Prasugrel With and Without a Glycoprotein IIb/IIIa Inhibitor in Patients With Acute Coronary Syndromes Undergoing Percutaneous Intervention
2009
Angiotensin-converting enzyme 2 protects from severe acute lung failure
2005 StandoutNature
Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery
2010
Regulatory Functions of the Vascular Endothelium
1990 StandoutNobel
Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial
2009
Platelet Inhibition with Cangrelor in Patients Undergoing PCI
2009
Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients
2009
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
2010
Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel
2008
Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial
2011
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies
2007 Standout
Is the normalisation of blood pressure in bleeding trauma patients harmful?
2001
Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation
1991 Standout
Platelets in atherothrombosis: lessons from mouse models
2005
Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin
2001 Standout
Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury.
1989
Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells
2007 Standout
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
2009 Standout
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
2007 Standout
ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)
2011 Standout
Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes
2011
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
2004 Standout
External validity of randomised controlled trials: “To whom do the results of this trial apply?”
2005 Standout
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
2009 Standout
Central role of the P2Y12 receptor in platelet activation
2004
Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study
2010
Extracellular vesicles: Exosomes, microvesicles, and friends
2013 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Open Multicentre Study of the P 2T Receptor Antagonist AR-C69931MX Assessing Safety, Tolerability and Activity in Patients with Acute Coronary Syndromes
2001
Platelet Activation and Blood Coagulation
2002
Upstream Clopidogrel Use and the Efficacy and Safety of Early Eptifibatide Treatment in Patients With Acute Coronary Syndrome
2011
Leukocyte lipid body formation and eicosanoid generation: cyclooxygenase-independent inhibition by aspirin.
1996 StandoutNobel
Clopidogrel Versus Dipyridamole in Addition to Aspirin in Reducing Embolization Detected With Ambulatory Transcranial Doppler
2011
Directed Evolution: Bringing New Chemistry to Life
2017 StandoutNobel
Inhibition of Platelet Aggregation by AZD6140, A Reversible Oral P2Y12Receptor Antagonist, Compared With Clopidogrel in Patients With Acute Coronary Syndromes
2007
Diabetes and Antiplatelet Therapy in Acute Coronary Syndrome
2011
Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies
2010
IMPROVED AORTOCORONARY BYPASS PATENCY BY LOW-DOSE ASPIRIN (100 mg DAILY)
1984
Defects in secretion, aggregation, and thrombus formation in platelets from mice lacking Akt2
2004
"AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia.
1983
Procoagulant Microparticles
2006
Biological actions and properties of endothelium-derived nitric oxide formed and released from artery and vein.
1989 StandoutNobel
Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: A randomized, single-blind, 30-day trial
2008
Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease
2009
Reporting Randomized, Controlled Trials of Herbal Interventions: An Elaborated CONSORT Statement
2006
G Protein-Coupled Receptors: Functional and Mechanistic Insights Through Altered Gene Expression
1998 StandoutNobel
A circadian gene expression atlas in mammals: Implications for biology and medicine
2014 Standout
Safety and Tolerability of Antiplatelet Therapies for the Secondary Prevention of Atherothrombotic Disease
2009
The platelet P2Y12 receptor for adenosine diphosphate: congenital and drug-induced defects
2010
Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man.
1983
EIGHTH GADDUM MEMORIAL LECTURE UNIVERSITY OF LONDON INSTITUTE OF EDUCATION DECEMBER 1980: BIOLOGICAL IMPORTANCE OF PROSTACYCLIN
1982
Platelet phosphatidylserine exposure and procoagulant activity in clotting whole blood – different effects of collagen, TRAP and calcium ionophore A23187
2003 StandoutNobel
Minimizing the Risks of Anticoagulants and Platelet Inhibitors
2010
A Comparison of Albumin and Saline for Fluid Resuscitation in the Intensive Care Unit
2004 Standout
HAEMOSTATIC FUNCTION AND ISCHAEMIC HEART DISEASE: PRINCIPAL RESULTS OF THE NORTHWICK PARK HEART STUDY
1986 Standout
Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs
1987
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
2012 Standout
Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets
2002
Clinical Aspects of Platelet Inhibitors and Thrombus Formation
2007
Angiotensin-converting enzyme and male fertility
1998 StandoutNobel
Putting polyphosphates to the test: evidence against platelet-induced activation of factor XII
2013 StandoutNobel
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
Clinical pharmacology of platelet cyclooxygenase inhibition.
1985
Stent Thrombosis With Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes
2013
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies
2007 Standout
Activation of Platelet Function Through G Protein–Coupled Receptors
2006
Oral Glycoprotein IIb/IIIa Inhibition With Orbofiban in Patients With Unstable Coronary Syndromes (OPUS-TIMI 16) Trial
2000
Dose Effect of Clopidogrel Reloading in Patients Already on 75-mg Maintenance Dose
2008
Human platelets synthesize and express functional tissue factor
2007
Alternate Heme Ligation Steers Activity and Selectivity in Engineered Cytochrome P450-Catalyzed Carbene-Transfer Reactions
2018 StandoutNobel
Selective Cumulative Inhibition of Platelet Thromboxane Production by Low-dose Aspirin in Healthy Subjects
1982 Standout
Clopidogrel Response Variability and Future Therapies
2006
Reduced growth, abnormal kidney structure, and type 2 (AT 2 ) angiotensin receptor-mediated blood pressure regulation in mice lacking both AT 1A and AT 1B receptors for angiotensin II
1998 StandoutNobel
Works of Stan Heptinstall being referenced
A regimen for low-dose aspirin?
1982
Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease
2002
Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations inP2RY12, P2RY1,andITGB3
2009
Effect of aspirin, clopidogrel and dipyridamole on soluble markers of vascular function in normal volunteers and patients with prior ischaemic stroke
2006
Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin
2006
Effects of aspirin, clopidogrel and dipyridamole administered singly and in combination on platelet and leucocyte function in normal volunteers and patients with prior ischaemic stroke
2005
Role of GPIIb-IIIa in platelet-monocyte and platelet-neutrophil conjugate formation in whole blood
1998
Effects of combining three different antiplatelet agents on platelets and leukocytes in whole blood in vitro
2001
The central role of the P2T receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity
2000
Acyl derivatives of coenzyme A inhibit platelet function via antagonism at P2Y1and P2Y12receptors: A new finding that may influence the design of anti-thrombotic agents
2008
Prospective double-blind randomized study of the effects of four intravenous fluids on platelet function and hemostasis in elective hip surgery
2003
Inhibitory effects of P2Y12receptor antagonists on TRAP-induced platelet aggregation, procoagulant activity, microparticle formation and intracellular calcium responses in patients with acute coronary syndromes
2005
Effects of gelatin-based resuscitation fluids on platelet aggregation
1998
Mode of action of P2Y12 antagonists as inhibitors of platelet function
2010
Interactions between prostaglandin E2 and inhibitors of platelet aggregation which act through cyclic AMP
1991
Effects of P2Y 1 and P2Y 12 receptor antagonists on platelet aggregation induced by different agonists in human whole blood
2001
Ticagrelor: a P2Y12antagonist for use in acute coronary syndromes
2012
Human blood platelet behaviour after inhibition of thromboxane synthetase.
1983
Inhibition of platelet aggregation by transdermal glyceryl trinitrate.
1994
Platelet Behaviour in Non-Insulin-Dependent Diabetes -Influence of Vascular Complications, Treatment and Metabolic Control
1986
Transfer of Tissue Factor from Platelets to Monocytes: Role of Platelet-Derived Microvesicles and CD62P
2002
The expression of glycoproteins on single blood platelets from healthy individuals and from patients with congenital bleeding disorders
1984
Mechanisms Involved in Adenosine Triphosphate–Induced Platelet Aggregation in Whole Blood
2003
Parthenolide Content and Bioactivity of Feverfew (Tanacetum parthenium (L.) Schultz-Bip.). Estimation of Commercial and Authenticated Feverfew Products
1992
Platelet Aggregation in Whole Blood Determined Using the Ultra-Flo 100 Platelet Counter
1982
Inhibition of ADP-induced P-selectin Expression and Platelet-Leukocyte Conjugate Formation by Clopidogrel and the P2Y12 Receptor Antagonist AR-C69931MX but not Aspirin
2002
Differential Effects of Glycoprotein IIb/IIIa Antagonists on Platelet Microaggregate and Macroaggregate Formation and Effect of Anticoagulant on Antagonist Potency
1998
DIFFERENTIAL INHIBITION BY LOW-DOSE ASPIRIN OF HUMAN VENOUS PROSTACYCLIN SYNTHESIS AND PLATELET THROMBOXANE SYNTHESIS
1981
Effects of ketanserin and mepyramine on platelet aggregation and on the uptake of 5-hydroxytryptamine into platelets
1983
A Comparison of the Effects of an Extract of Feverfew and Parthenolide, a Component of Feverfew, on Human Platelet Activity In-vitro
1990
A Study of the Use of the Thromboxane A2 Antagonist, Sulotroban, in Combination with Streptokinase for Local Thrombolysis in Patients with Recent Peripheral Arterial Occlusions: Clinical Effects, Platelet Function and Fibrinolytic Parameters
1993